Median Technologies Reports 93.3% Sensitivity for Lung Cancer Screening Device in Clinical Study
Median Technologies will present study results supporting eyonis LCS lung cancer screening software at CHEST on October 19, 2026, in Phoenix. The 2,163-patient study suggests the device reduces false positives and missed cancers, supporting more consistent clinical decisions. The software received FDA 510(k) clearance